source
- Analysts Question Biogen's Lupus Drug Litifilimab Ahead of Key Phase 3 ReadoutsAnalysts pressed Biogen CEO Chris Viehbacher during a recent call, focusing on the company's late‑stage pipeline. The discussion centered on litifilimab, Biogen’s experimental lupus therapy, with…
- FDA releases draft guidance to streamline approval of personalized gene therapiesThe FDA announced a draft guidance aimed at expanding access to gene therapies that target different mutations within the same disease. The proposal outlines an "individualized feature space" that…